WELCOME TO THE

ADD-ASPIRIN WEBSITE

This website is designed to provide information about the Add-Aspirin Trial, both for people taking part in the trial (participants) and collaborators. Please use the menus at the top of the screen to find out more about the trial.           

Add-Aspirin is a large randomised clinical trial, which is taking place in the UK and India. It will recruit 11,000 participants to help find out whether regular aspirin use after treatment for an early stage cancer can prevent the cancer from coming back and preventing deaths.

News

June 2015
Researchers suggest that people taking aspirin regularly may have a lower risk of cancer
Read more

May 2015
Daily Telegraph: Aspirin can increase risk of bowel cancer for some, study suggests
Read more

Quick links for
NHS professionals


REGISTER A PARTICIPANT

UNBLIND A PARTICIPANT

 

BREAST


We aim to recruit 3100 individuals who have had surgery to remove an early stage breast cancer. 

CURRENT STATUS:
NOT YET OPEN 

Detailed eligibility criteria available here   

 

PARTICIPANTS REGISTERED:
PARTICIPANTS RANDOMISED:
      

COLON/RECTUM 


We aim to to recruit 2600 individuals who have had surgery to remove an early stage bowel cancer. 

CURRENT STATUS:
NOT YET OPEN 

Detailed eligibility criteria available here 

 

PARTICIPANTS REGISTERED:
PARTICIPANTS RANDOMISED:

STOMACH/OESOPHAGUS 


We aim to recruit 2100 individuals who have had surgery or a combination of chemotherapy and radiotherapy to treat a cancer of the stomach or oesophagus (food pipe).

CURRENT STATUS:
NOT YET OPEN 

Detailed eligibility criteria available here 

PARTICIPANTS REGISTERED:
PARTICIPANTS RANDOMISED:

PROSTATE


We aim to recruit 2120 individuals who have had surgery or radiotherapy to treat an early stage prostate cancer. 

CURRENT STATUS:
NOT YET OPEN 

Detailed eligibility criteria available here    

                                              PARTICIPANTS REGISTERED:
PARTICIPANTS RANDOMISED:
        

The trial is being jointly funded by Cancer Research UK (grant number C471 /A15015, www.cancerresearchuk.org), the National Institute for Health Research Health Technology Assessment Programme (project number 12/01/38, www.nihr.ac.uk) and the MRC Clinical Trials Unit at UCL.
© Add-Aspirin, MRC CTU at UCL